WO1999001463A3 - Modified glycosides, compositions comprised thereof and methods of use thereof - Google Patents

Modified glycosides, compositions comprised thereof and methods of use thereof Download PDF

Info

Publication number
WO1999001463A3
WO1999001463A3 PCT/GB1998/001962 GB9801962W WO9901463A3 WO 1999001463 A3 WO1999001463 A3 WO 1999001463A3 GB 9801962 W GB9801962 W GB 9801962W WO 9901463 A3 WO9901463 A3 WO 9901463A3
Authority
WO
WIPO (PCT)
Prior art keywords
modified glycosides
methods
variety
glass matrix
delivery systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1998/001962
Other languages
French (fr)
Other versions
WO1999001463A2 (en
Inventor
Camilo Colaco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Quadrant Holdings Cambridge Ltd
Original Assignee
Quadrant Holdings Cambridge Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quadrant Holdings Cambridge Ltd filed Critical Quadrant Holdings Cambridge Ltd
Priority to DK98932361T priority Critical patent/DK0994887T3/en
Priority to AT98932361T priority patent/ATE228528T1/en
Priority to JP50667799A priority patent/JP2002510316A/en
Priority to DE69809746T priority patent/DE69809746T2/en
Priority to AU82299/98A priority patent/AU8229998A/en
Priority to EP98932361A priority patent/EP0994887B1/en
Publication of WO1999001463A2 publication Critical patent/WO1999001463A2/en
Publication of WO1999001463A3 publication Critical patent/WO1999001463A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Modified glycosides are provided which can be used to form a variety of materials including solid delivery systems, and optically clear coloured devices or coatings. The solid delivery systems can be used for delivery and release of a variety of substances can be in the form of tablets for oral administration, or in the form of powders, microspheres or implants for intravenous, intradermal, transdermal, pulmonary or other route of administration. The modified glycosides may be processed to form a vitreous glass matrix having a substance, such as a therapeutic agent, or an optically active dye incorporated therein. In one embodiment, the vitreous glass matrix is provided in a solid dose form which is capable of releasing a therapeutic substance in situ at various controlled rates.
PCT/GB1998/001962 1997-07-03 1998-07-03 Modified glycosides, compositions comprised thereof and methods of use thereof Ceased WO1999001463A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK98932361T DK0994887T3 (en) 1997-07-03 1998-07-03 Modified glycosides, preparations included therein and methods for their use
AT98932361T ATE228528T1 (en) 1997-07-03 1998-07-03 MODIFIED GLYCOSIDES, COMPOSITIONS CONTAINING MODIFIED GLYCOSIDES AND METHODS FOR THE PRODUCTION THEREOF
JP50667799A JP2002510316A (en) 1997-07-03 1998-07-03 Modified glycosides, compositions containing the same and methods of using the same
DE69809746T DE69809746T2 (en) 1997-07-03 1998-07-03 MODIFYING GLYCOSIDES, COMPOSITIONS CONTAINING MODIFIED GLYCOSIDES AND METHOD FOR THE PRODUCTION THEREOF
AU82299/98A AU8229998A (en) 1997-07-03 1998-07-03 Modified glycosides, compositions comprised thereof and methods of use thereof
EP98932361A EP0994887B1 (en) 1997-07-03 1998-07-03 Modified glycosides, compositions comprised thereof and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5172797P 1997-07-03 1997-07-03
US60/051,727 1997-07-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11192598A A-371-Of-International 1997-07-03 1998-07-08
US09/923,023 Continuation US20020009464A1 (en) 1997-07-03 2001-08-06 Modified glycosides, compositions comprised thereof and methods of use thereof

Publications (2)

Publication Number Publication Date
WO1999001463A2 WO1999001463A2 (en) 1999-01-14
WO1999001463A3 true WO1999001463A3 (en) 1999-03-25

Family

ID=21973024

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/001962 Ceased WO1999001463A2 (en) 1997-07-03 1998-07-03 Modified glycosides, compositions comprised thereof and methods of use thereof

Country Status (9)

Country Link
EP (1) EP0994887B1 (en)
JP (1) JP2002510316A (en)
AT (1) ATE228528T1 (en)
AU (1) AU8229998A (en)
DE (1) DE69809746T2 (en)
DK (1) DK0994887T3 (en)
ES (1) ES2187038T3 (en)
PT (1) PT994887E (en)
WO (1) WO1999001463A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6352722B1 (en) 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
GB9916316D0 (en) 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
AU2001244391B9 (en) 2000-04-03 2006-10-05 Ventaira Pharmaceuticals, Inc. Devices and formulations
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
EP1343521A2 (en) 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
EP3251722B1 (en) * 2001-04-20 2020-06-17 ALZA Corporation Microprojection array having a beneficial agent containing coating and method of forming the coating thereon
GB0208608D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Composition
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
JP4722386B2 (en) * 2003-08-22 2011-07-13 広島県 Glycolipid and method for producing the same
CA2574958A1 (en) * 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
WO2007013160A1 (en) 2005-07-28 2007-02-01 Saga University Radical sterilization apparatus
US20250011369A1 (en) * 2021-11-05 2025-01-09 Institute Of Process Engineering, Chinese Academy Of Sciences Cyclopeptide Glass and Pharmaceutical Composition Glass Containing Cyclopeptide
CN114014908B (en) * 2021-11-05 2023-08-22 中国科学院过程工程研究所 Cyclic peptide glass and pharmaceutical composition glass containing cyclic peptide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003978A1 (en) * 1994-08-04 1996-02-15 Quadrant Holdings Cambridge Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEBAULT, GWENDOLYN M. ET AL: "Synthesis of 4-O-.beta.-D-mannopyranosyl-L-rhamnopyranose", 1974, CARBOHYDR. RES. (1974), 37(2), 309-19 CODEN: CRBRAT, XP002085499 *
COLOMBO, DIEGO ET AL: "Optically pure 1-O- and 3-O-.beta.-D-glucosyl- and galactosyl-sn-glycerols through lipase-catalyzed transformations", 1995, TETRAHEDRON LETT. (1995), 36(27), 4865-8 CODEN: TELEAY;ISSN: 0040-4039, XP004027788 *
NANASI, P. ET AL: "Synthesis of O-.alpha.-D-glucopyranosyl-(1.fwdarw. 4)-O-.beta.-D-glucopyranosyl-(1.fwdarw. 6)-D-glucose", 1976, ACTA CHIM. ACAD. SCI. HUNG. (1976), 88(2), 154-8 CODEN: ACASA2, XP002085500 *
STANLEY PEAT ET AL.: "The structure of Laminarin. Part III. Synthesis of structural Oligosaccharides.", J. CHEM. SOC., - 1960, pages 175 - 178, XP002085498 *

Also Published As

Publication number Publication date
ES2187038T3 (en) 2003-05-16
DK0994887T3 (en) 2003-03-17
AU8229998A (en) 1999-01-25
DE69809746T2 (en) 2004-09-30
EP0994887B1 (en) 2002-11-27
WO1999001463A2 (en) 1999-01-14
DE69809746D1 (en) 2003-01-09
JP2002510316A (en) 2002-04-02
ATE228528T1 (en) 2002-12-15
EP0994887A2 (en) 2000-04-26
PT994887E (en) 2003-04-30

Similar Documents

Publication Publication Date Title
AU8229998A (en) Modified glycosides, compositions comprised thereof and methods of use thereof
ZA9811843B (en) Derivatized carbohydrates compositions comprised thereof and methods for use thereof
EP2266542A3 (en) Controlled release nanoparticulate compositions
AU7465087A (en) Controlled release bioerodible drug delivery system
AU635021B2 (en) Extended release pharmaceutical formulations
PL343829A1 (en) Adhesive microsphere drug delivery composition
CA2312710A1 (en) Sustained release formulation containing three different types of polymers and tablet formed therefrom
AR002754A1 (en) PHARMACEUTICAL COMPOSITION COMPRISING MICRO-ENCAPSULATED VIABLE LACTOBACILLUS BACTERIA, AND USE OF THE COMPOSITION TO PREPARE A MEDICINAL PRODUCT
BR9912495B1 (en) "NOCICEPTIN RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS UNDERSTANDING THE SAME AND ITS USES IN THE MANUFACTURE OF MEDICINAL PRODUCTS"
IE880281L (en) Swellable pellets
DK0789559T3 (en) A pharmaceutical composition containing a fusible carrier and a process for its preparation
ZA985392B (en) New derivatives of 2-(iminomethyl) amino-phenyl, their preparation their use as medicaments and the pharmaceutical compositions containing them
ATE349203T1 (en) DELAVIRDINE TABLET FORMULATION
AU6404398A (en) New derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
HUP0002517A3 (en) Derivatives of acyl-piperazinil-pyrimidins, preparation thereof, pharmaceutical compositions containing them and their use as medicaments
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EE9600202A (en) Carbamazepine sustained release formulation
CA2356306A1 (en) Sulfated phosphatidylinositols, their preparation and use
HUP0200529A3 (en) Optically pure camptothecin analogues, pharmaceutical compositions containing them and their use
DE69823299D1 (en) Process for the preparation of pharmaceutical compositions containing bromazepam in the form of spherical pills or granules for controlled and delayed release and compositions prepared
JPS57183714A (en) Medicinal pharmaceutical
AU5041190A (en) Transdermal drug delivery composition
EP0416722A3 (en) Pharmaceutical compositions having differential drug release rate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998932361

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998932361

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1998932361

Country of ref document: EP